Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod - 14/03/12
, Jennifer Armstrong, MS a, e, Yu-Chih Huang, PhD a, c, Leila Elkeeb, MD a, b, Arisa Ortiz, MD a, b, Ronald Harris, MD, MBA b, Bernard Choi, PhD a, d, Kristen M. Kelly, MD a, b
Reprint requests: Anne Marie Tremaine, MD, Department of Dermatology, University of California, Irvine, C340 Medical Sciences 1, Irvine, CA 92697-2400.Abstract |
Background |
Pulsed dye laser (PDL) is the gold standard for treatment of port-wine stain (PWS) birthmarks but multiple treatments are required and complete resolution is often not achieved. Posttreatment vessel recurrence is thought to be a factor that limits efficacy of PDL treatment of PWS. Imiquimod 5% cream is an immunomodulator with antiangiogenic effects.
Objective |
We sought to determine if application of imiquimod 5% cream after PDL improves treatment outcome.
Methods |
Healthy individuals with PWS (n = 24) were treated with PDL and then randomized to apply posttreatment placebo or imiquimod 5% cream for 8 weeks. Chromameter measurements (Commission Internationale de l’Eclairage Lab colorspace) for 57 PWS sites (multiple sites per patient) were taken at baseline and compared with measurements taken 8 weeks posttreatment. The Δa (change in erythema) and ΔE (difference in color between normal-appearing skin and PWS skin) were measured to quantify treatment outcome.
Results |
Two patients developed minor skin irritation. Other adverse effects were not noted. Average ∆a was 0.43 for PDL + placebo sites (n = 25) and 1.27 for PDL + imiquimod sites (n = 32) (P value = .0294) indicating a greater reduction in erythema with imiquimod. Average ∆E was 2.59 for PDL + placebo and 4.08 for PDL + imiquimod (P value = .0363), again indicating a greater color improvement with imiquimod.
Limitations |
Effects were evaluated after a single treatment and duration of effect is unknown.
Conclusion |
Combined selective photothermolysis and antiangiogenic therapy may enhance PWS treatment efficacy.
Le texte complet de cet article est disponible en PDF.Key words : angiogenesis, imiquimod, port-wine stain, pulsed dye laser, selective photothermolysis, vascular malformation
Abbreviations used : bFGF, IL, MMP, PDL, PWS, VEGF
Plan
| Supported in part by grants from the American Society for Laser Medicine and Surgery (Dr Kelly), the National Institutes of Health (NIH) (AR51443 to Dr Kelly), the A. Ward Ford Foundation (Dr Choi), and Graceway Pharmaceuticals. Imiquimod and placebo cream were provided by Graceway Pharmaceuticals. Equipment was from Candela Corp. Institutional support was provided by the NIH Laser Microbeam and Medical Program (a P41 Technology Research Resource), NIH EB009571 (Dr Choi), and the Arnold and Mabel Beckman Foundation. |
|
| Disclosure: Dr Kelly received grants from Graceway Pharmaceuticals, Candela Corp, DUSA. She also has relationships with Solta Medical (equipment and grants) and DUSA (equipment and grant). Drs Tremaine, Huang, Elkeeb, Ortiz, Harris, and Choi, and Ms Armstrong have no conflicts of interest to declare. |
Vol 66 - N° 4
P. 634-641 - avril 2012 Retour au numéro
Article précédent
- Prospective randomized controlled clinical and histopathological study of acne vulgaris treated with dual mode of quasi-long pulse and Q-switched 1064-nm Nd:YAG laser assisted with a topically applied carbon suspension
- Jae Yoon Jung, Jong Soo Hong, Chang Ho Ahn, Ji Young Yoon, Hyuck Hoon Kwon, Dae Hun Suh
- The histopathological characteristics of male melasma: Comparison with female melasma and lentigo
- Yong Hyun Jang, Ji Hyun Sim, Hee Young Kang, You Chan Kim, Eun-So Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?